ChREBP regulates fructose-induced glucose production independently of insulin signaling
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
Obese, insulin-resistant states are characterized by a paradoxical pathogenic condition in which the liver appears to be selectively insulin resistant. Specifically, insulin fails to suppress glucose production, yet successfully stimulates de novo lipogenesis. The mechanisms underlying this dysregulation remain controversial. Here, we hypothesized that carbohydrate-responsive element-binding protein (ChREBP), a transcriptional activator of glycolytic and lipogenic genes, plays a central role in this paradox. Administration of fructose increased hepatic hexose-phosphate levels, activated ChREBP, and caused glucose intolerance, hyperinsulinemia, hypertriglyceridemia, and hepatic steatosis in mice. Activation of ChREBP was required for the increased expression of glycolytic and lipogenic genes as well as glucose-6-phosphatase (G6pc) that was associated with the effects of fructose administration. We found that fructose-induced G6PC activity is a major determinant of hepatic glucose production and reduces hepatic glucose-6-phosphate levels to complete a homeostatic loop. Moreover, fructose activated ChREBP and induced G6pc in the absence of Foxo1a, indicating that carbohydrate-induced activation of ChREBP and G6PC dominates over the suppressive effects of insulin to enhance glucose production. This ChREBP/G6PC signaling axis is conserved in humans. Together, these findings support a carbohydrate-mediated, ChREBP-driven mechanism that contributes to hepatic insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is in line with the results from some studies in that hepatic esterification of FAs into TG, unlike DNL, depends on substrate delivery rather than insulin action [84-86].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [86]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ChREBPβ is transcriptionally induced by ChREBPα and amplifies the glucose response in the liver and adipose tissue [78,86].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Supporting this perspective, monosaccharides have been shown to activate ChREBP and other key lipogenic transcription factors—including SREBP1c, LXR, and PPARγ—via insulin-independent mechanisms [34,70,83,86,99].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the Western diet not only contains large amounts of AGEs, due to high levels of food processing, but is also high in fat and sugar, particularly fructose, which increases AGE production in the body, in part, by increasing circulating glucose levels via enhanced hepatic glucose production and insulin resistance.[4]”
From The Role of Dietary Advanced Glycation End Products in Metabolic Dysfunction (2021) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In response to the intake of large carbohydrates, fructose could enhance hepatic lipogenic capacity by inducing hepatic master transcription factors.93 94 95”
From Dietary sugar consumption and health: umbrella review (2023) · cites this paper as [94]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism
Taniguchi, C. M., Ueki, K., & Kahn, C. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23187 · Cited by 272
RetractedA SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“These studies do not address the observation that hyperinsulinemia fails to suppress hepatic glucose-6-phosphatase ( G6PC ) expression in insulin-resistant humans (12), a condition where increased DNL in association with steatosis and hypertriglyceridemia is readily apparent (13, 14).”
BackgroundSugar-Sweetened Beverages and Risk of Metabolic Syndrome and Type 2 Diabetes
Malik, V. S., Popkin, B. M., Bray, G. A., Després, J.-P., Willett, W. C., & Hu, F. B. (2010) · Diabetes Care · doi:10.2337/dc10-1079 · Cited by 2,116
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003) · Nature · doi:10.1038/nature01667 · Cited by 1,487
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322 · cited 1×
“However, others reported that defects in hepatic insulin signaling occur at the level of the insulin receptor, proximal to the proposed branch points in insulin signaling, thereby precluding differential insulin signaling as a mechanism to explain this paradox (7).”
Background
Cited by
Items 201–212 of 212
Li, Y., Guo, R., Qian, Y., Hawro, I., Córdoba‐Chacón, J., Jiang, Y., & Song, Z. (2026) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00379.2025
Huang, J., Wu, F., Chen, W., Ye, D., Tian, Y., Li, J., Guo, J., Wang, J., Mao, Y., & Sun, X. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1680542
“Fructose is rapidly metabolized in the liver (33), bypassing the rate-limiting step of glycolysis and promoting the activation of carbohydrate-responsive element-binding protein (34), which may drive lipogenesis and glucose metabolism (35).”
Self-citationWang, J., Liu, X., Liu, F., Zuo, L., Wang, Y., Wang, L., Xiong, Y., Song, G., Song, K., Cheng, Y., et al. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6480006
Self-citationThe role of the circadian transcription factor KLF10 in liver physiology
Ruberto, A. A. (2019) · theses.fr (ABES) · doi:10.70675/cb3492c2z5778z48e3za7d7zf17279fd718b
Recazens, E. (2021) · theses.fr (ABES) · doi:10.70675/5b66fe82zcbbbz4251z98c0z2bb967f598c2
Inter-organ communication in physiology and pathophysiology : a role for the ChREBP-FGF21 axis?
Carbinatti, T. (2024) · theses.fr (ABES) · doi:10.70675/5d147ab4zad37z4f6bzac51z32a08efeaa51
ChREBP Is Dispensable for Myofiber Type Switch but Promotes Skeletal Muscle Regeneration
Lu, J., Chen, J., Zhang, G., Ma, H., Sun, P., Wang, C., Yu, X., Feng, K., Wang, C., Hu, C., et al. (2026) · Nutrients · doi:10.3390/nu18122012
Fructose and Alcohol Hepatotoxicity: Demographic Overlap and Mechanistic Interactions
Stem, A. D., Lisgara, A., Alayyoub, M., Berardi, D., Aladelokun, O. B., Johnson, C. H., Johnson, R. J., & Vasiliou, V. (2026) · Livers · doi:10.3390/livers6050092
“Similarly, fructose upregulates lipogenic gene expression while acting as a potent stimulator of ChREBP, a sugar-responsive transcription factor that functions independent of insulin signaling [74,75].”
Abnormal lipid metabolism in metabolic dysfunction-associated steatohepatitis (MASH)
Lee, W., Choi, Y., Park, H., Chae, S., & Lee, B. (2026) · Toxicological Research · doi:10.1007/s43188-026-00387-3
Metadata
- Authors
- Kim, M.-S., Krawczyk, S. A., Doridot, L., Fowler, A. J., Wang, J. X., Trauger, S. A., Noh, H.-L., Kang, H. J., Meissen, J. K., Blatnik, M., Kim, J. K., Lai, M., & Herman, M. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- University of Massachusetts Chan Medical School (US)
- Pfizer (United States) (US)
- Broad Institute (US)
- Corresponding author
- Herman, Mark A.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2016-09-26
- Volume
- 126
- Issue
- 11
- Pages
- 4372-4386
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5096918
- OpenAlex
- W2521958286
- Cited by
- 212
- References
- 69
- Citations by year
- 2026: 13 · 2025: 21 · 2024: 12 · 2023: 21 · 2022: 24 · 2021: 21 · 2020: 32 · 2019: 30 · 2018: 15 · 2017: 21 · 2016: 2
- FWCI
- 23.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@UMassChan (submittedVersion)
- Funders
- National Institutes of Health (5u2cdk093000-11)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK057521, U24DK093000, U2C-DK093000, R01DK100425, K23DK083439, T32DK007516)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- ChREBP, fructose, hepatic glucose production, hepatic insulin resistance, glucose-6-phosphatase, glucose-6-phosphate, FOXO1, hepatic steatosis, hypertriglyceridemia, hyperinsulinemia, impaired glucose tolerance, de novo lipogenesis, glycolytic genes, carbohydrate metabolism
- MeSH terms
- Forkhead Box Protein O1, Animals, Fatty Liver, Female, Fructose, Glucose, Glucose-6-Phosphatase, Glycolysis, Humans, Insulin, Insulin Resistance, Male, Nuclear Proteins, Transcription Factors, Signal Transduction, Glucose Intolerance, Mice, Knockout, Lipogenesis, Mice, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.